Supernus Pharmaceuticals (SUPN) Cost of Revenue (2013 - 2025)

Supernus Pharmaceuticals (SUPN) has 13 years of Cost of Revenue data on file, last reported at $23.0 million in Q4 2025.

• On a quarterly basis, Cost of Revenue fell 11.84% year-over-year to $23.0 million in Q4 2025; TTM through Dec 2025 was $74.6 million, a 4.29% decrease from a year earlier, with the FY2025 full-year figure at $74.6 million, down 4.29% from the prior year.
• Cost of Revenue for Q4 2025 stood at $23.0 million, up from $19.0 million in the prior quarter.
• Over the last five years, Cost of Revenue for SUPN reached as high as $26.1 million in Q4 2024 and fell as low as $15.0 million in Q1 2021.
• Historically, Cost of Revenue has averaged $19.9 million across 5 years, with a median of $19.3 million in 2023.
• Across the five-year window, Cost of Revenue soared 260.16% in 2021 and tumbled 30.48% in 2024, its largest moves.
• Year by year, Cost of Revenue stood at $17.0 million in 2021, then jumped by 35.07% to $23.0 million in 2022, then dropped by 14.49% to $19.6 million in 2023, then jumped by 32.97% to $26.1 million in 2024, then slipped by 11.84% to $23.0 million in 2025.
• Per Business Quant data, the three most recent Cost of Revenue figures were $23.0 million in Q4 2025, $19.0 million in Q3 2025, and $16.8 million in Q2 2025.